Medicine shortages loom over Iran hospitals, pharmacies

Key Concepts

• Supply Chain Disruption: The breakdown of logistics networks due to geopolitical conflict.
• Naval Blockade: A military strategy to prevent the passage of goods into or out of a country.
• API (Active Pharmaceutical Ingredient): The biologically active component of a drug product that produces the intended health effect.
• Intermediate Products: Substances produced during the steps of processing that must undergo further molecular change before becoming an API.
• Strait of Hormuz: A critical maritime chokepoint for global trade and supply chains.

Impact of Geopolitical Conflict on Iran’s Pharmaceutical Sector

Current Supply Chain Crisis

The ongoing conflict involving Iran, the United States, and Israel has resulted in severe disruptions to the country's pharmaceutical supply chain. The primary catalyst for these shortages is a naval blockade and significant disruptions in the Strait of Hormuz, which have effectively hampered the flow of essential goods. Furthermore, the cessation of air cargo operations has prevented the timely delivery of critical medical supplies.

Hospital-Level Impacts and Inventory Status

At Avicenna Hospital in Tehran, Chief Arash Anisian reports that the facility is already facing acute shortages in three specific categories:

• Chemotherapy drugs: Critical for cancer treatment.
• Analgesics: Pain-relieving medications.
• Hypertension medications: Essential for managing high blood pressure.

Regarding inventory, Anisian provided a specific timeline for the hospital's sustainability:

• Finished Medications: Approximately 2 months of stock remaining.
• API and Intermediate Products: Approximately 2 months of raw materials available for domestic manufacturing.

Anisian noted that disruptions in the petrochemical sector—a vital industry for the production of pharmaceutical precursors—could further exacerbate these shortages if the conflict persists.

Perspectives on Resilience and Long-term Outlook

While medical staff acknowledge that Iran has successfully mitigated widespread shortages of essential goods thus far, there is growing concern regarding the long-term viability of these stocks. The consensus among healthcare workers is that while the immediate crisis is being managed, the sustainability of the healthcare system is precarious if supply lines remain severed.

Notable Statements

• Arash Anisian (Chief of Avicenna Hospital): "In my opinion, we have only 2 months medication in the storage and 2 months API and intermediate products to manufacturing the medications."
• Anisian on the nature of the crisis: "It's normal in any escalations like war, you may face on the shortage of medications."

Diplomatic Developments

The report highlights a significant diplomatic shift: U.S. President Donald Trump announced a unilateral extension of a ceasefire with Iran. This extension is intended to provide a window for discussing an Iranian proposal aimed at ending the two-month-old conflict.

Synthesis and Conclusion

The pharmaceutical landscape in Iran is currently defined by a race against time. With only a two-month buffer of both finished drugs and raw manufacturing materials (APIs), the healthcare system is highly vulnerable to the ongoing naval blockade and air cargo suspensions. While diplomatic efforts toward a ceasefire are underway, the immediate operational reality for hospitals like Avicenna is one of resource rationing and concern over the potential for a total depletion of critical medical supplies if the geopolitical impasse continues.